Newswise — TAMPA, Fla. (Oct. 28, 2011) – The National Cancer Institute recently awarded $7.2 million for the competitive renewal of the Southeast Phase 2 Consortium (SEP2C), led by Moffitt Cancer Center’s Daniel Sullivan, M.D., executive vice president and associate center director for Clinical Investigations. The renewal is through September 2016.
The SEP2C enrolls patients to phase II clinical trials and some phase I trials across six member sites. Moffitt is the lead site for the large contract that is awarded through the NCI’s N01 research and development contract mechanism. The first year is projected to provide nearly $1.5 million.
The other member sites are UNC Lineberger Comprehensive Cancer; Vanderbilt-Ingram Cancer Center; Winship Cancer Institute of Emory University; VCU Massey Cancer Center; and the Cancer Institute of New Jersey.
Patient accrual at Moffitt will be focused on the following cancers: acute myeloid leukemia, breast, colorectal, lung, myelodysplastic syndrome, melanoma, multiple myeloma, non-Hodgkin's lymphoma, ovarian and sarcoma, as well as on immunotherapy and novel phase I trials. The consortium provides full management of the clinical trials including initiation, assessing eligibility, recruitment, evaluation of toxicity and response, auditing, follow-up, and analysis of results.
About Moffitt Cancer CenterFollow Moffitt on Facebook: www.facebook.com/MoffittCancerCenter
Follow Moffitt on Twitter: @MoffittNews
Follow Moffitt on YouTube: MoffittNews
Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center – a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt marks a very important anniversary in 2011 – 25 years committed to one mission: to contribute to the prevention and cure of cancer.
###
RSS